Skip to main content

Table 2 Comparison of BMI, HbA1c, FPG, Basal and Bolus Insulin Doses at Baseline and 26 weeks after IDeg Treatment by Age

From: Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population

Characteristics Baseline 26 weeks
BMI (kg/m2) (SDS)
 Overall population (N = 30) 16.99 ± 3.364 (0.04 ± 0.97) 17.39 ± 3.005 (0.15 ± 0.89)
 1–6 years (n = 8) 15.28 ± 1.274 (0.04 ± 0.81) 15.83 ± 1.199 (0.48 ± 0.63)
 6–12 years (n = 14) 16.79 ± 3.297 (0.10 ± 0.91) 17.18 ± 2.653 (0.20 ± 0.91)
  > 12 years (n = 8) 19.04 ± 4.108 (− 0.16 ± 1.11) 19.33 ± 3.964 (− 0.15 ± 1.06)
HbA1c (%)
 Overall population (N = 30) 9.65 ± 1.998 8.60 ± 1.631*
 1–6 years (n = 8) 8.59 ± 0.753 8.31 ± 0.930
 6–12 years (n = 14) 10.32 ± 2.213 8.50 ± 1.024*#
  > 12 years (n = 8) 9.53 ± 2.159 9.06 ± 2.802
FPG (mg/dL)
 Overall population (N = 30) 156.93 ± 42.373 109.37 ± 28.531*
 1–6 years (n = 8) 136.50 ± 12.862 105.75 ± 26.114*
 6–12 years (n = 14) 176.43 ± 49.781 108.36 ± 28.678*
  > 12 years (n = 8) 143.25 ± 34.919 114.75 ± 33.363*
Insulin dose (U/kg of body weight/day)
 Basal insulin
  Overall population (N = 30) 0.42 ± 0.134 0.46 ± 0.139*
  1–6 years (n = 8) 0.38 ± 0.120 0.41 ± 0.109
  6–12 years (n = 14) 0.46 ± 0.165 0.52 ± 0.163
   > 12 years (n = 8) 0.40 ± 0.069 0.41 ± 0.074
 Bolus insulin
  Overall population (N = 30) 0.49 ± 0.208 0.35 ± 0.155*
  1–6 years (n = 8) 0.37 ± 0.115 0.27 ± 0.077*
  6–12 years (n = 14) 0.57 ± 0.255 0.39 ± 0.176*
   > 12 years (n = 8) 0.48 ± 0.128 0.37 ± 0.156*
  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, SDS Standard Deviation Score
  2. *P < 0.05 versus baseline (paired t-test)
  3. #P < 0.05 versus 1–6 years (t-test)
\